

Carlamaria Zoja

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8381785/carlamaria-zoja-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

126
papers

9,118
citations

51
h-index

94
g-index

128
ext. papers

9,901
ext. citations

7.5
avg, IF

5.45
L-index

#	Paper	IF	Citations
126	Shiga Toxin 2 Triggers C3a-Dependent Glomerular and Tubular Injury through Mitochondrial Dysfunction in Hemolytic Uremic Syndrome. <i>Cells</i> , 2022 , 11, 1755	7.9	1
125	CER-001 ameliorates lipid profile and kidney disease in a mouse model of familial LCAT deficiency. <i>Metabolism: Clinical and Experimental</i> , 2021 , 116, 154464	12.7	3
124	Characterization of a Rat Model of Myeloperoxidase-Anti-Neutrophil Cytoplasmic Antibody-Associated Crescentic Glomerulonephritis. <i>Nephron</i> , 2021 , 145, 428-444	3.3	2
123	Post-translational modifications by SIRT3 de-2-hydroxyisobutyrylase activity regulate glycolysis and enable nephrogenesis. <i>Scientific Reports</i> , 2021 , 11, 23580	4.9	1
122	C3a receptor blockade protects podocytes from injury in diabetic nephropathy. <i>JCI Insight</i> , 2020 , 5,	9.9	17
121	Manipulating Sirtuin 3 pathway ameliorates renal damage in experimental diabetes. <i>Scientific Reports</i> , 2020 , 10, 8418	4.9	18
120	Protective Effects of Human Nonrenal and Renal Stromal Cells and Their Conditioned Media in a Rat Model of Chronic Kidney Disease. <i>Cell Transplantation</i> , 2020 , 29, 963689720965467	4	
119	Diabetic Nephropathy: Novel Molecular Mechanisms and Therapeutic Targets. <i>Frontiers in Pharmacology</i> , 2020 , 11, 586892	5.6	13
118	A preclinical overview of emerging therapeutic targets for glomerular diseases. <i>Expert Opinion on Therapeutic Targets</i> , 2019 , 23, 593-606	6.4	6
117	Addition of cyclic angiotensin-(1-7) to angiotensin-converting enzyme inhibitor therapy has a positive add-on effect in experimental diabetic nephropathy. <i>Kidney International</i> , 2019 , 96, 906-917	9.9	23
116	Deficiency Shortens Life Span and Impairs Cardiac Mitochondrial Function Rescued by Gene Transfer. <i>Antioxidants and Redox Signaling</i> , 2019 , 31, 1255-1271	8.4	33
115	Alteration of thyroid hormone signaling triggers the diabetes-induced pathological growth, remodeling, and dedifferentiation of podocytes. <i>JCI Insight</i> , 2019 , 4,	9.9	9
114	Complement Activation Contributes to the Pathophysiology of Shiga Toxin-Associated Hemolytic Uremic Syndrome. <i>Microorganisms</i> , 2019 , 7,	4.9	12
113	Shiga toxin triggers endothelial and podocyte injury: the role of complement activation. <i>Pediatric Nephrology</i> , 2019 , 34, 379-388	3.2	20
112	Fenofibrate attenuates cardiac and renal alterations in young salt-loaded spontaneously hypertensive stroke-prone rats through mitochondrial protection. <i>Journal of Hypertension</i> , 2018 , 36, 1129-1146	1.9	5
111	ADAMTS13 Deficiency Shortens the Life Span of Mice With Experimental Diabetes. <i>Diabetes</i> , 2018 , 67, 2069-2083	0.9	4
110	Therapeutic potential of stromal cells of non-renal or renal origin in experimental chronic kidney disease. <i>Stem Cell Research and Therapy</i> , 2018 , 9, 220	8.3	19

109	SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy. <i>JCI Insight</i> , 2018 , 3,	9.9	57
108	MicroRNA-184 is a downstream effector of albuminuria driving renal fibrosis in rats with diabetic nephropathy. <i>Diabetologia</i> , 2017 , 60, 1114-1125	10.3	44
107	B7-1 Is Not Induced in Podocytes of Human and Experimental Diabetic Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2016 , 27, 999-1005	12.7	21
106	Simplified Method to Measure Glomerular Filtration Rate by Iohexol Plasma Clearance in Conscious Rats. <i>Nephron</i> , 2016 , 133, 62-70	3.3	6
105	Therapy with a Selective Cannabinoid Receptor Type 2 Agonist Limits Albuminuria and Renal Injury in Mice with Type 2 Diabetic Nephropathy. <i>Nephron</i> , 2016 , 132, 59-69	3.3	30
104	Lipoprotein X Causes Renal Disease in LCAT Deficiency. <i>PLoS ONE</i> , 2016 , 11, e0150083	3.7	43
103	A previously unrecognized role of C3a in proteinuric progressive nephropathy. <i>Scientific Reports</i> , 2016 , 6, 28445	4.9	18
102	Key pathways in renal disease progression of experimental diabetes. <i>Nephrology Dialysis Transplantation</i> , 2015 , 30 Suppl 4, iv54-9	4.3	14
101	Et and diabetic nephropathy: preclinical and clinical studies. <i>Seminars in Nephrology</i> , 2015 , 35, 188-96	4.8	13
100	Mitochondrial-dependent Autoimmunity in Membranous Nephropathy of IgG4-related Disease. <i>EBioMedicine</i> , 2015 , 2, 456-66	8.8	17
99	Renal primordia activate kidney regenerative events in a rat model of progressive renal disease. <i>PLoS ONE</i> , 2015 , 10, e0120235	3.7	14
98	Effects of MCP-1 inhibition by bindarit therapy in a rat model of polycystic kidney disease. <i>Nephron</i> , 2015 , 129, 52-61	3.3	35
97	Progression of renal injury toward interstitial inflammation and glomerular sclerosis is dependent on abnormal protein filtration. <i>Nephrology Dialysis Transplantation</i> , 2015 , 30, 706-12	4.3	65
96	Arrestin-1 drives endothelin-1-mediated podocyte activation and sustains renal injury. <i>Journal of the American Society of Nephrology: JASN</i> , 2014 , 25, 523-33	12.7	54
95	The Nrf2 pathway in the progression of renal disease. <i>Nephrology Dialysis Transplantation</i> , 2014 , 29 Suppl 1, i19-i24	4.3	98
94	Shiga toxin promotes podocyte injury in experimental hemolytic uremic syndrome via activation of the alternative pathway of complement. <i>Journal of the American Society of Nephrology: JASN</i> , 2014 , 25, 1786-98	12.7	39
93	Angiotensin II contributes to diabetic renal dysfunction in rodents and humans via Notch1/Snail pathway. <i>American Journal of Pathology</i> , 2013 , 183, 119-30	5.8	33
92	Analogues of bardoxolone methyl worsen diabetic nephropathy in rats with additional adverse effects. <i>American Journal of Physiology - Renal Physiology</i> , 2013 , 304, F808-19	4.3	77

91	Renal expression of FGF23 in progressive renal disease of diabetes and the effect of ACE inhibitor. <i>PLoS ONE</i> , 2013 , 8, e70775	3.7	68
90	Mesenchymal stem cell therapy promotes renal repair by limiting glomerular podocyte and progenitor cell dysfunction in adriamycin-induced nephropathy. <i>American Journal of Physiology - Renal Physiology</i> , 2012 , 303, F1370-81	4.3	71
89	Increased renal versican expression is associated with progression of chronic kidney disease. <i>PLoS ONE</i> , 2012 , 7, e44891	3.7	15
88	Evaluation of the Zucker diabetic fatty (ZDF) rat as a model for human disease based on urinary peptidomic profiles. <i>PLoS ONE</i> , 2012 , 7, e51334	3.7	45
87	Lack of the lectin-like domain of thrombomodulin worsens Shiga toxin-associated hemolytic uremic syndrome in mice. <i>Journal of Immunology</i> , 2012 , 189, 3661-8	5.3	29
86	Effect of ACE inhibition on glomerular permselectivity and tubular albumin concentration in the renal ablation model. <i>American Journal of Physiology - Renal Physiology</i> , 2011 , 300, F1291-300	4.3	12
85	Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. <i>Journal of Immunology</i> , 2011 , 187, 172-80	5.3	186
84	Distinct cardiac and renal effects of ETA receptor antagonist and ACE inhibitor in experimental type 2 diabetes. <i>American Journal of Physiology - Renal Physiology</i> , 2011 , 301, F1114-23	4.3	51
83	Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection. <i>American Journal of Physiology - Renal Physiology</i> , 2010 , 299, F1203-11	4.3	45
82	Life-sparing effect of human cord blood-mesenchymal stem cells in experimental acute kidney injury. <i>Stem Cells</i> , 2010 , 28, 513-22	5.8	152
81	Shiga toxin-associated hemolytic uremic syndrome: pathophysiology of endothelial dysfunction. <i>Pediatric Nephrology</i> , 2010 , 25, 2231-40	3.2	137
80	The role of chemokines in progressive renal disease. <i>Frontiers in Bioscience - Landmark</i> , 2009 , 14, 1815-22.8		34
79	Protein load impairs factor H binding promoting complement-dependent dysfunction of proximal tubular cells. <i>Kidney International</i> , 2009 , 75, 1050-9	9.9	24
78	Thrombomodulin mutations in atypical hemolytic-uremic syndrome. <i>New England Journal of Medicine</i> , 2009 , 361, 345-57	59.2	418
77	V1/V2 Vasopressin receptor antagonism potentiates the renoprotection of renin-angiotensin system inhibition in rats with renal mass reduction. <i>Kidney International</i> , 2009 , 76, 960-7	9.9	46
76	Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes. <i>American Journal of Physiology - Renal Physiology</i> , 2009 , 297, F1448-56	4.3	97
75	Proteasomal processing of albumin by renal dendritic cells generates antigenic peptides. <i>Journal of the American Society of Nephrology: JASN</i> , 2009 , 20, 123-30	12.7	74
74	Disruption of the Ang II type 1 receptor promotes longevity in mice. <i>Journal of Clinical Investigation</i> , 2009 , 119, 524-30	15.9	374

73	Complement-mediated dysfunction of glomerular filtration barrier accelerates progressive renal injury. <i>Journal of the American Society of Nephrology: JASN</i> , 2008 , 19, 1158-67	12.7	54
72	Fractalkine and CX3CR1 mediate leukocyte capture by endothelium in response to Shiga toxin. <i>Journal of Immunology</i> , 2008 , 181, 1460-9	5.3	35
71	Human bone marrow mesenchymal stem cells accelerate recovery of acute renal injury and prolong survival in mice. <i>Stem Cells</i> , 2008 , 26, 2075-82	5.8	326
70	Involvement of renal tubular Toll-like receptor 9 in the development of tubulointerstitial injury in systemic lupus. <i>Arthritis and Rheumatism</i> , 2007 , 56, 1569-78		51
69	Cyclin-dependent kinase inhibition limits glomerulonephritis and extends lifespan of mice with systemic lupus. <i>Arthritis and Rheumatism</i> , 2007 , 56, 1629-37		42
68	Effects of rosuvastatin on glomerular capillary size-selectivity function in rats with renal mass ablation. <i>American Journal of Nephrology</i> , 2007 , 27, 630-8	4.6	11
67	Insulin-like growth factor-1 sustains stem cell mediated renal repair. <i>Journal of the American Society of Nephrology: JASN</i> , 2007 , 18, 2921-8	12.7	264
66	Rosuvastatin treatment prevents progressive kidney inflammation and fibrosis in stroke-prone rats. <i>American Journal of Pathology</i> , 2007 , 170, 1165-77	5.8	61
65	Transcriptional regulation of nephrin gene by peroxisome proliferator-activated receptor-gamma agonist: molecular mechanism of the antiproteinuric effect of pioglitazone. <i>Journal of the American Society of Nephrology: JASN</i> , 2006 , 17, 1624-32	12.7	73
64	Beneficial effect of TGFbeta antagonism in treating diabetic nephropathy depends on when treatment is started. <i>Nephron Experimental Nephrology</i> , 2006 , 104, e158-68		36
63	Shigatoxin-induced endothelin-1 expression in cultured podocytes autocrinally mediates actin remodeling. <i>American Journal of Pathology</i> , 2006 , 169, 1965-75	5.8	85
62	How does proteinuria cause progressive renal damage?. <i>Journal of the American Society of Nephrology: JASN</i> , 2006 , 17, 2974-84	12.7	544
61	Progression of chronic kidney disease: insights from animal models. <i>Current Opinion in Nephrology and Hypertension</i> , 2006 , 15, 250-7	3.5	36
60	Imatinib ameliorates renal disease and survival in murine lupus autoimmune disease. <i>Kidney International</i> , 2006 , 70, 97-103	9.9	66
59	In response to protein load podocytes reorganize cytoskeleton and modulate endothelin-1 gene: implication for permselective dysfunction of chronic nephropathies. <i>American Journal of Pathology</i> , 2005 , 166, 1309-20	5.8	131
58	Genetics of rare diseases of the kidney: learning from mouse models. <i>Cytogenetic and Genome Research</i> , 2004 , 105, 479-84	1.9	4
57	Targeted deletion of angiotensin II type 1A receptor does not protect mice from progressive nephropathy of overload proteinuria. <i>Journal of the American Society of Nephrology: JASN</i> , 2004 , 15, 2666-74	12.7	28
56	Vasopeptidase inhibitor restores the balance of vasoactive hormones in progressive nephropathy. <i>Kidney International</i> , 2004 , 66, 1959-65	9.9	43

55	Mesenchymal stem cells are renotropic, helping to repair the kidney and improve function in acute renal failure. <i>Journal of the American Society of Nephrology: JASN</i> , 2004 , 15, 1794-804	12.7	615
54	Cellular responses to protein overload: key event in renal disease progression. <i>Current Opinion in Nephrology and Hypertension</i> , 2004 , 13, 31-7	3.5	117
53	Add-on anti-TGF-beta antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat. <i>Journal of the American Society of Nephrology: JASN</i> , 2003 , 14, 1816-24	12.7	160
52	Combining lisinopril and l-arginine slows disease progression and reduces endothelin-1 in passive Heymann nephritis. <i>Kidney International</i> , 2003 , 64, 857-63	9.9	11
51	Protein overload induces fractalkine upregulation in proximal tubular cells through nuclear factor kappaB- and p38 mitogen-activated protein kinase-dependent pathways. <i>Journal of the American Society of Nephrology: JASN</i> , 2003 , 14, 2436-46	12.7	105
50	Effect of combining ACE inhibitor and statin in severe experimental nephropathy. <i>Kidney International</i> , 2002 , 61, 1635-45	9.9	88
49	Proximal tubular cells promote fibrogenesis by TGF-beta1-mediated induction of peritubular myofibroblasts. <i>Kidney International</i> , 2002 , 61, 2066-77	9.9	97
48	Shiga toxin-2 triggers endothelial leukocyte adhesion and transmigration via NF-kappaB dependent up-regulation of IL-8 and MCP-1. <i>Kidney International</i> , 2002 , 62, 846-56	9.9	94
47	How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach. <i>Journal of the American Society of Nephrology: JASN</i> , 2002 , 13, 2898-908	12.7	131
46	Transforming growth factor-beta1 is up-regulated by podocytes in response to excess intraglomerular passage of proteins: a central pathway in progressive glomerulosclerosis. <i>American Journal of Pathology</i> , 2002 , 161, 2179-93	5.8	116
45	Verotoxin-1-induced up-regulation of adhesive molecules renders microvascular endothelial cells thrombogenic at high shear stress. <i>Blood</i> , 2001 , 98, 1828-35	2.2	81
44	Mycophenolate mofetil combined with a cyclooxygenase-2 inhibitor ameliorates murine lupus nephritis. <i>Kidney International</i> , 2001 , 60, 653-63	9.9	45
43	Shear stress-induced cytoskeleton rearrangement mediates NF-kappaB-dependent endothelial expression of ICAM-1. <i>Microvascular Research</i> , 2000 , 60, 182-8	3.7	25
42	Protein traffic activates NF-kB gene signaling and promotes MCP-1-dependent interstitial inflammation. <i>American Journal of Kidney Diseases</i> , 2000 , 36, 1226-41	7.4	134
41	Protein overload activates proximal tubular cells to release vasoactive and inflammatory mediators. <i>Nephron Experimental Nephrology</i> , 1999 , 7, 420-8		40
40	Renoprotection by nitric oxide donor and lisinopril in the remnant kidney model. <i>American Journal of Kidney Diseases</i> , 1999 , 33, 746-53	7.4	40
39	Xenogeneic human serum promotes leukocyte adhesion to porcine endothelium under flow conditions, possibly through the activation of the transcription factor NF-kappa B. <i>Xenotransplantation</i> , 1998 , 5, 57-60	2.8	12
38	Renoprotective effect of contemporary blocking of angiotensin II and endothelin-1 in rats with membranous nephropathy. <i>Kidney International</i> , 1998 , 54, 353-9	9.9	63

37	Experimental Goodpasture's syndrome in Wistar-Kyoto rats immunized with alpha3 chain of type IV collagen. <i>Kidney International</i> , 1998 , 54, 1550-61	9.9	39
36	Bindarit retards renal disease and prolongs survival in murine lupus autoimmune disease. <i>Kidney International</i> , 1998 , 53, 726-34	9.9	63
35	Protein overload stimulates RANTES production by proximal tubular cells depending on NF-kappa B activation. <i>Kidney International</i> , 1998 , 53, 1608-15	9.9	324
34	Pharmacologic control of angiotensin II ameliorates renal disease while reducing renal TGF-beta in experimental mesangioproliferative glomerulonephritis. <i>American Journal of Kidney Diseases</i> , 1998 , 31, 453-63	7.4	51
33	Angiotensin II blockade limits tubular protein overreabsorption and the consequent upregulation of endothelin 1 gene in experimental membranous nephropathy. <i>Nephron Experimental Nephrology</i> , 1998 , 6, 121-31		36
32	Leukocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NF-kB-dependent fashion. <i>Journal of Clinical Investigation</i> , 1998 , 101, 1905-15	15.9	316
31	The renoprotective properties of angiotensin-converting enzyme inhibitors in a chronic model of membranous nephropathy are solely due to the inhibition of angiotensin II: evidence based on comparative studies with a receptor antagonist. <i>American Journal of Kidney Diseases</i> , 1997 , 29, 254-64	7.4	67
30	Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease. <i>Kidney International</i> , 1997 , 51, 1583-9	9.9	114
29	Renal and systemic nitric oxide synthesis in rats with renal mass reduction. <i>Kidney International</i> , 1997 , 52, 171-81	9.9	112
28	Cyclosporine enhances leukocyte adhesion to vascular endothelium under physiologic flow conditions. <i>American Journal of Kidney Diseases</i> , 1996 , 28, 23-31	7.4	24
27	Blocking both type A and B endothelin receptors in the kidney attenuates renal injury and prolongs survival in rats with remnant kidney. <i>American Journal of Kidney Diseases</i> , 1996 , 27, 416-23	7.4	88
26	Increased nitric oxide formation in recurrent thrombotic microangiopathies: a possible mediator of microvascular injury. <i>American Journal of Kidney Diseases</i> , 1996 , 27, 790-6	7.4	42
25	A study of low-nutrient diets used for aging studies in the rat. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 1996 , 51, B270-5	6.4	2
24	Role of platelets in progressive glomerular diseases. <i>Pediatric Nephrology</i> , 1995 , 9, 495-502	3.2	30
23	Proximal tubular cell synthesis and secretion of endothelin-1 on challenge with albumin and other proteins. <i>American Journal of Kidney Diseases</i> , 1995 , 26, 934-41	7.4	211
22	Glomerulonephritis. <i>Current Opinion in Nephrology and Hypertension</i> , 1993 , 2, 465-74	3.5	9
21	Reduced fibrinolytic activity in glomeruli isolated from rabbits infused with tumor necrosis factor. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 1993 , 23, 173-8		1
20	Interleukin-1 and glomerular mesangial cells. <i>Kidney and Blood Pressure Research</i> , 1993 , 16, 89-92	3.1	3

19	Interleukin-6 stimulates gene expression of extracellular matrix components in bovine mesangial cells in culture. <i>Mediators of Inflammation</i> , 1993 , 2, 429-33	4.3	3
18	A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression. <i>Kidney International</i> , 1993 , 44, 440-4	9.9	180
17	Renal endothelin gene expression is increased in remnant kidney and correlates with disease progression. <i>Kidney International</i> , 1993 , 43, 354-8	9.9	119
16	Renal protective effect of angiotensin-converting enzyme inhibition in aging rats. <i>American Journal of Medicine</i> , 1992 , 92, 60S-63S	2.4	22
15	Turnour necrosis factor stimulates endothelin-1 gene expression in cultured bovine endothelial cells. <i>Mediators of Inflammation</i> , 1992 , 1, 263-6	4.3	4
14	Interleukin-1 regulates cytokine gene expression in human mesangial cells through the interleukin-1 receptor type 1. <i>Journal of the American Society of Nephrology: JASN</i> , 1992 , 2, 1709-15	12.7	10
13	The effect of caloric restriction on a rat model of aging: biological, pathological, biochemical and behavioral characterization. <i>Aging Clinical and Experimental Research</i> , 1991 , 3, 388-90	4.8	
12	Oral zeranol shortens the prolonged bleeding time of uremic rats. <i>Kidney International</i> , 1990 , 38, 96-100	9.9	5
11	Endothelin and eicosanoid synthesis in cultured mesangial cells. <i>Kidney International</i> , 1990 , 37, 927-33	9.9	23
10	Ticlopidine prevents renal disease progression in rats with reduced renal mass. <i>Kidney International</i> , 1990 , 37, 934-42	9.9	24
9	Role of endothelium-derived nitric oxide in the bleeding tendency of uremia. <i>Journal of Clinical Investigation</i> , 1990 , 86, 1768-71	15.9	81
8	Abnormalities in arachidonic acid metabolites in nephrotoxic glomerular injury. <i>Toxicology Letters</i> , 1989 , 46, 65-75	4.4	6
7	Indomethacin reduces proteinuria in passive Heymann nephritis in rats. <i>Kidney International</i> , 1987 , 31, 1335-43	9.9	49
6	Tubulo-interstitial lesions mediate renal damage in adriamycin glomerulopathy. <i>Kidney International</i> , 1986 , 30, 488-96	9.9	131
5	Partial isolation and function of the prostacyclin regulating plasma factor. <i>Clinical Science</i> , 1985 , 69, 383-93	9.9	22
4	Low-protein diet prevents glomerular damage in adriamycin-treated rats. <i>Kidney International</i> , 1985 , 28, 21-7	9.9	42
3	Lack of synergism between dazoxiben and dipyridamole following administration to man. <i>Thrombosis Research</i> , 1985 , 37, 231-6	8.2	3
2	Plasmatic regulation of vascular prostacyclin in pregnancy. <i>British Medical Journal</i> , 1981 , 282, 512-4		43

- 1 Reduced umbilical and placental vascular prostacyclin in severe pre-eclampsia. *Prostaglandins*, **1980**, 20, 105-10

212